ReviewCurrent hypertension reports2015
Medical Therapies for the Treatment of Pulmonary Arterial Hypertension: How Do We Choose?
Review in Current hypertension reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oxygen-sensitivity and Pulmonary Selectivity of Vasodilators as Potential Drugs for Pulmonary Hypertension.Antioxidants (Basel, Switzerland) · 2021Article
- Catching a Disease: A Molecular Trap as a Therapy for Pulmonary Arterial Hypertension.American journal of respiratory and critical care medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Significant advances have been made in the management of pulmonary arterial hypertension (PAH) in the past decade. There is a greater understanding of the disease process, more robust markers of prognostication and a wider range of disease-targeted therapies, with three classes of drug therapy now established. This has resulted in improved prognosis and quality of life but has also increased the complexity in making treatment decisions. To utilise these pharmacotherapies to their best potential, several factors need to be considered. This article will discuss how best to initiate and escalate PAH therapy on an individual patient basis by discussing current pharmacotherapies available, specific patient factors and determining treatment response and prognosis at diagnosis and during follow-up.
Indexed as
Identifiers
26068652What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.